Targets › EGLN1
5 programs from 5 companies in 9 trials: 3 Phase 3, 3 Phase 4, 2 Phase 1, 1 Phase 2; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs…. (UniProt, Q9GZT9)
Open in Phaseline: the race on EGLN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Zhongshan Hospital | Enarodustat Egl nine homolog 1 inhibitor | EGLN1 | Phase 4 | Chronic Kidney Disease Associated Anemia | Jan 2029 |
| Zydus Lifesciences | Desidustat PHD inhibitor | EGLN1, EGLN2, EGLN3 | Phase 4 | Chronic Kidney Diseases | – |
| Astellas | Roxadustat Hypoxia-inducible factor prolyl hydroxylase inhibitor | EGLN2, P4HTM, EGLN1, EGLN3 | Phase 3 | Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic … | Oct 2027 |
| USRC Kidney Research | Vadadustat Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor | EGLN1, EGLN3, EGLN2 | Phase 3 | Anemia of Chronic Kidney Disease | – |
| Paul Potnuru | Vadadustat Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor | EGLN1, EGLN3, EGLN2 | Phase 2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | May 2031 |
Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1) Anemia of Chronic Kidney Disease (1) Chronic Kidney Diseases (1) Chronic Kidney Disease Associated Anemia (1) Nonintubated Acute Respiratory Distress Syndrome (ARDS) (1)
small molecule (4), mixed (1)
Astellas (1) USRC Kidney Research (1) Zydus Lifesciences (1) Shanghai Zhongshan Hospital (1) Paul Potnuru (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.